Over the past 12 months, $CORT has been mentioned 6 times by 2 distinct FinTwit voices, with biotech analyst Adam Feuerstein (@adamfeuerstein) accounting for 5 of those mentions. The stock first appeared in the archive on February 5, 2026, and has been discussed most recently as of March 26, 2026. The conversation centers on Corcept Therapeutics' drug relacorilant, which the FDA approved for advanced ovarian cancer despite earlier skepticism about safety concerns.

Feuerstein, the most active voice discussing $CORT, initially expressed doubt about regulatory approval due to liver injury risk and higher side effect rates but acknowledged being wrong when the FDA granted approval on March 25, 2026. Following the approval, discussion shifted to examining the prescribing label details, with both Feuerstein and Jacob Plieth (@jacobplieth) noting concerns about the safety profile and drug interactions listed for Lifyorli, the branded name for relacorilant.